NCT00451035

Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase

A Phase II, Multicentre Study of Oral LBH589 in Patients With Chronic Phase Chronic Myeloid Leukemia With Resistant Disease Following Treatment With at Least Two Fusion Gene of the BCR and ABL Genes (BCR-ABL) Tyrosine Kinase Inhibitors

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy and safety of LBH589B in adult patients with chronic phase chronic myeloid leukemia with resistant disease following treatment with at least two BCR-ABL tyrosine kinase inhibitors

Conditions

• Chronic Myeloid Leukemia in Chronic Phase

Interventions

Type	Name	Description
DRUG	LBH589

Timeline

• Start date: 2007-02-19
• Primary completion: 2008-04-13
• Completion: 2008-09-30
• First posted: 2007-03-22
• Last updated: 2021-07-15
• Results posted: 2021-07-14

Locations

10 sites across 2 countries: Belgium, Germany